Sumitomo Pharma Co., Ltd.
4506
Rankning i aktier
#3223
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Aktiekurs
$12.27
Marknadsvärde
$5.51B
Förändring (1 dag)
2.20%
Förändring (1 år)
6.72%
Land
JP
Handel Sumitomo Pharma Co., Ltd. (4506)
Kategori
Healthcare
Rörelsemarginal för Sumitomo Pharma Co., Ltd. (4506)
Rörelsemarginal per October 2026 TTM: 10.05%
Enligt de senaste finansiella rapporterna och aktiekursen för Sumitomo Pharma Co., Ltd. är företagets nuvarande rörelsemarginal (TTM) 10.05%. Vid slutet av 2024 var rörelsemarginalen -112.60%.
Historik för rörelsemarginal för Sumitomo Pharma Co., Ltd. från 2005 till 2026
Rörelsemarginal vid slutet av varje år
| År | Rörelsemarginal | Ändra |
|---|---|---|
| 2026 (TTM) | 10.05% | 39.20% |
| 2025 | 7.22% | -106.41% |
| 2024 | -112.60% | 712.41% |
| 2023 | -13.86% | -228.81% |
| 2022 | 10.76% | -22.03% |
| 2021 | 13.80% | -19.95% |
| 2020 | 17.24% | 36.83% |
| 2019 | 12.60% | -33.30% |
| 2018 | 18.89% | 47.35% |
| 2017 | 12.82% | 39.96% |
| 2016 | 9.16% | 46.09% |
| 2015 | 6.27% | -42.32% |
| 2014 | 10.87% | 50.97% |
| 2013 | 7.20% | 23.71% |
| 2012 | 5.82% | -28.68% |
| 2011 | 8.16% | -32.11% |
| 2010 | 12.02% | 1.86% |
| 2009 | 11.80% | -21.75% |
| 2008 | 15.08% | -13.53% |
| 2007 | 17.44% | 48.43% |
| 2006 | 11.75% | 77.49% |
| 2005 | 6.62% | 0.00% |
Rörelsemarginal för liknande företag eller konkurrenter
| Företag | Rörelsemarginal | Skillnad i rörelsemarginal | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -97.72% |
IN
|
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.